US FDA proposes to streamline de novo medical device review pathway
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration is seeking feedback on proposals to streamline the "cumbersome" de novo review programme that is it uses for certain innovative, low- to moderate-risk devices that cannot be cleared by the pre-market notification, or 510(k), process. The proposals are expected to trim off up to 90 days from the de novo programme.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.